Suppr超能文献

急性近端深静脉血栓形成的管理:依诺肝素门诊治疗与普通肝素住院治疗的药物经济学评估

Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.

作者信息

Spyropoulos Alex C, Hurley Judith S, Ciesla Gabrielle N, de Lissovoy Gregory

机构信息

Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA.

出版信息

Chest. 2002 Jul;122(1):108-14. doi: 10.1378/chest.122.1.108.

Abstract

OBJECTIVES

A landmark Canadian randomized controlled clinical trial compared treatment of acute proximal vein thrombosis via low-molecular-weight heparin (LMWH) [enoxaparin] administered primarily at home with IV unfractionated heparin (UH) in the hospital. Results demonstrated equivalent safety and efficacy for home care with enoxaparin with a reduction in cost. Our objective was to validate these findings in the routine practice setting of a US health maintenance organization.

DESIGN

Retrospective analysis of medical and administrative records of health-plan members meeting inclusion-exclusion criteria of the Canadian trial during the period from 1995 to 1998.

SETTING

Staff-model health maintenance organization serving New Mexico.

PATIENTS

Persons presenting as outpatients from 1995 to 1996 or from 1997 to 1998 with acute, proximal deep vein thrombosis (DVT) diagnosed by duplex ultrasonography.

INTERVENTIONS

Initial anticoagulant therapy of IV UH administered in the hospital (from 1995 to 1996 group, n = 64) or subcutaneous LMWH (enoxaparin) administered primarily at home (from 1997 to 1998 group, n = 65), followed by warfarin therapy.

RESULTS

No statistically significant differences were observed in the number of recurrent venous thromboembolic events (p = 0.36) or bleeding events (p = 1.0). Mean +/- SD cost per patient was 9,347 dollars +/- 8,469 in the enoxaparin group compared with 11,930 dollars +/- 10,892 in the UH group, a difference of - 2,583 dollars (95% bootstrap-adjusted asymmetrical confidence interval, - 6,147 dollars, + 650 dollars).

CONCLUSIONS

Retrospective replication of the Canadian study in a US routine (managed) care setting found similar clinical and economic outcomes. Treatment of acute proximal DVT with enoxaparin in a primarily outpatient setting can be accomplished safely and yields savings through avoidance or minimization of inpatient stays.

摘要

目的

一项具有里程碑意义的加拿大随机对照临床试验,比较了通过主要在家中使用的低分子量肝素(LMWH)[依诺肝素]治疗急性近端静脉血栓形成与在医院使用静脉注射普通肝素(UH)的疗效。结果表明,依诺肝素家庭护理在安全性和疗效方面相当,且成本降低。我们的目的是在美国健康维护组织的常规实践环境中验证这些发现。

设计

对1995年至1998年期间符合加拿大试验纳入 - 排除标准的健康计划成员的医疗和行政记录进行回顾性分析。

背景

为新墨西哥州服务的员工模式健康维护组织。

患者

1995年至1996年或1997年至1998年期间以门诊患者身份就诊,经双功超声诊断为急性近端深静脉血栓形成(DVT)的患者。

干预措施

在医院进行静脉注射普通肝素的初始抗凝治疗(1995年至1996年组,n = 64)或主要在家中进行皮下低分子量肝素(依诺肝素)治疗(1997年至1998年组,n = 65),随后进行华法林治疗。

结果

在复发性静脉血栓栓塞事件数量(p = 0.36)或出血事件(p = 1.0)方面未观察到统计学上的显著差异。依诺肝素组每位患者的平均成本±标准差为9347美元±8469美元,而普通肝素组为11930美元±10892美元,差异为 - 2583美元(95%自展法调整的不对称置信区间, - 6147美元,+ 650美元)。

结论

在美国常规(管理式)护理环境中对加拿大研究进行回顾性复现,发现了相似的临床和经济结果。在主要为门诊环境中使用依诺肝素治疗急性近端DVT可以安全完成,并通过避免或尽量减少住院时间节省费用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验